Abstract 225: Regulation Of Plasma Lipoproteins And Atherosclerosis By Microrna-541-3p And Transcription Factors Znf101 And Casz1

Abulaish Ansari,Pradeep Kumar Yada,Liye Zhou,Laraib Ijaz,Amanda christiano,Sameer Ahmad,Antoine Rimbert,M M Hussain

DOI: https://doi.org/10.1161/atvb.43.suppl_1.225

2023-05-01

Abstract:High apoB-containing low-density lipoproteins (LDL) and low apoA1-containing high-density lipoproteins (HDL) are associated with atherosclerotic cardiovascular disease. MicroRNAs (miRs) are small non-coding RNAs that modulate multiple pathways. We screened a miR library in human liver cells and identified miR-541-3p that decreases apoB and increases apoA1 by inducing the degradation of mRNAs of two different transcription factors, Znf101 and Casz1. Molecular and physiological studies revealed that Znf101 enhances apoB expression and that Casz1 represses apoA1 expression. Thus, miR-541-3p differentially regulates apoB and apoA1 expression by reducing the expression of an enhancer and a repressor. Moreover, the hepatic knockdown of orthologous genes in mice reduced plasma lipids and atherosclerosis. Mechanistic studies revealed that lower hepatic lipoprotein production and increased HDL cholesterol efflux capacity might contribute to reductions in atherosclerosis. In addition, these livers showed reduced expression of genes involved in lipogenesis. Furthermore, knockdown of these genes and overexpression of miR-541-3p in human liver cells reduced lipogenesis. Thus, in addition, to apolipoprotein/lipoprotein production, miR-541-3p also regulates hepatic lipid synthesis. By screening human genetic datasets, we found that genetic variants in MIR541 , ZNF101 and CASZ1 loci are significantly associated with plasma lipid and lipoprotein levels. This study suggests miR-541-3p, Znf101 and Casz1 as potential therapeutic agents/targets to reduce plasma lipids, lipoproteins and atherosclerosis without causing steatosis.

peripheral vascular disease,hematology